Business Description
EyePoint Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US30233G1004
Description
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.03 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.27 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.5 | |||||
| Beneish M-Score | -2.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -23.9 | |||||
| 3-Year EBITDA Growth Rate | 13.8 | |||||
| 3-Year EPS without NRI Growth Rate | 19.7 | |||||
| 3-Year FCF Growth Rate | 67.1 | |||||
| 3-Year Book Growth Rate | 74.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -25.51 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -45.04 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.02 | |||||
| 9-Day RSI | 63.11 | |||||
| 14-Day RSI | 62.51 | |||||
| 6-1 Month Momentum % | -54.6 | |||||
| 12-1 Month Momentum % | 39.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.75 | |||||
| Quick Ratio | 4.69 | |||||
| Cash Ratio | 4.51 | |||||
| Days Inventory | 346.13 | |||||
| Days Sales Outstanding | 24.09 | |||||
| Days Payable | 806.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -39.3 | |||||
| Shareholder Yield % | 4.08 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.35 | |||||
| Operating Margin % | -195.71 | |||||
| Net Margin % | -172.3 | |||||
| FCF Margin % | -187.25 | |||||
| ROE % | -50.45 | |||||
| ROA % | -32.29 | |||||
| ROIC % | -160.76 | |||||
| 3-Year ROIIC % | -164.53 | |||||
| ROC (Joel Greenblatt) % | -629.38 | |||||
| ROCE % | -42.37 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.16 | |||||
| PB Ratio | 2.62 | |||||
| Price-to-Tangible-Book | 2.62 | |||||
| EV-to-EBIT | -4.1 | |||||
| EV-to-EBITDA | -4.14 | |||||
| EV-to-Revenue | 7.06 | |||||
| EV-to-Forward-Revenue | 15.13 | |||||
| EV-to-FCF | -3.77 | |||||
| Price-to-Median-PS-Value | 1.21 | |||||
| Price-to-Net-Current-Asset-Value | 3 | |||||
| Price-to-Net-Cash | 3.24 | |||||
| Earnings Yield (Greenblatt) % | -24.39 | |||||
| FCF Yield % | -15.4 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:EYPT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
EyePoint Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 50.391 | ||
| EPS (TTM) ($) | -1.78 | ||
| Beta | 2.09 | ||
| Volatility % | 285.12 | ||
| 14-Day RSI | 62.51 | ||
| 14-Day ATR ($) | 1.015578 | ||
| 20-Day SMA ($) | 9.938 | ||
| 12-1 Month Momentum % | 39.93 | ||
| 52-Week Range ($) | 5.855 - 30.99 | ||
| Shares Outstanding (Mil) | 53.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
EyePoint Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
EyePoint Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
EyePoint Pharmaceuticals Inc Frequently Asked Questions
What is EyePoint Pharmaceuticals Inc(EYPT)'s stock price today?
The current price of EYPT is $11.45. The 52 week high of EYPT is $30.99 and 52 week low is $5.86.
When is next earnings date of EyePoint Pharmaceuticals Inc(EYPT)?
The next earnings date of EyePoint Pharmaceuticals Inc(EYPT) is .
Does EyePoint Pharmaceuticals Inc(EYPT) pay dividends? If so, how much?
EyePoint Pharmaceuticals Inc(EYPT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers